Tag Archives: CytomX Therapeutics Inc

CytomX Therapeutics Inc (CTMX) Receives a Buy from Mizuho Securities

In a report issued on August 8, Mara Goldstein from Mizuho Securities reiterated a Buy rating on CytomX Therapeutics Inc (CTMX – Research Report), with a price target of $16. The company’s shares closed on Friday at $10.15, close to

Nomura Thinks CytomX Therapeutics Inc’s Stock is Going to Recover

In a report issued on August 8, Christopher Marai from Nomura maintained a Buy rating on CytomX Therapeutics Inc (CTMX – Research Report), with a price target of $22. The company’s shares closed on Friday at $10.15, close to its

Mizuho Securities Sticks to Its Buy Rating for CytomX Therapeutics Inc (CTMX)

In a report issued on July 26, Mara Goldstein from Mizuho Securities reiterated a Buy rating on CytomX Therapeutics Inc (CTMX – Research Report), with a price target of $16. The company’s shares closed on Friday at $10.18, close to

Cantor Fitzgerald Thinks CytomX Therapeutics Inc’s Stock is Going to Recover

Cantor Fitzgerald analyst Varun Kumar initiated coverage with a Buy rating on CytomX Therapeutics Inc (CTMX – Research Report) today and set a price target of $21. The company’s shares opened today at $10.75, close to its 52-week low of

CytomX Therapeutics Inc (CTMX) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on CytomX Therapeutics Inc (CTMX – Research Report) today and set a price target of $34. The company’s shares opened today at $10.80, close to its 52-week low of $9.38. Selvaraju

Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics Inc (CTMX), Allena Pharmaceuticals Inc (ALNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CytomX Therapeutics Inc (CTMX – Research Report) and Allena Pharmaceuticals Inc (ALNA – Research Report) with bullish sentiments. CytomX Therapeutics Inc (CTMX)